Literature DB >> 21068647

Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients.

Katherine A Barraclough1, Nicole M Isbel, Michael E Franklin, Katie J Lee, Paul J Taylor, Scott B Campbell, William G Petchey, Christine E Staatz.   

Abstract

Multiple limited sampling strategies (LSSs) have been proposed for estimation of mycophenolic acid (MPA) area under the concentration-time curve from 0 to 12 hours postdose (AUC 0-12) after mycophenolate mofetil intake. The aim of this study was to provide summary information on all published LSSs for MPA and to evaluate their predictive performance in an independent population of kidney transplant recipients. Seventy-eight LSSs for MPA were identified. Sixty-nine full AUC profiles were collected from 45 subjects (25 cotreated with cyclosporine and 20 with tacrolimus). Predicted MPA AUC 0-12, calculated by applying the relevant concentration measurements within the LSS equations, was compared with full AUC calculated by using all concentration measurements in the linear trapezoidal rule. Four error indices (median prediction error, median percentage prediction error [MPPE], root median squared prediction error, and median absolute percentage prediction error [MAPE]) were used to evaluate bias and imprecision. Twelve of the 25 LSSs for cyclosporine-cotreated recipients and one of the 53 LSSs for tacrolimus-cotreated recipients displayed acceptable (less than 15%) bias and imprecision. In the cyclosporine group, two equations demonstrated the highest predictive power, one that used four time points in the first 6 hours postdose (r2 = 0.84, MPPE 1.6%, MAPE 7.8%) and one that used four time points in the first 4 hours postdose (r2 = 0.76, MPPE -0.8%, MAPE 10.2%). In the tacrolimus group, an equation that used two time points in the first 4 hours postdose was superior (r2 = 0.80, MPPE -3.0%, MAPE 13.6%). Application of the LSSs most appropriate for cyclosporine-cotreated patients to the tacrolimus-cotreated group resulted in clinically unacceptable bias and imprecision and vice versa. High variability in performance of LSSs highlights the importance of validating any LSS before applying it to an alternative population. Attention to comedication use is of particular relevance when choosing a LSS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068647     DOI: 10.1097/FTD.0b013e3181fc8fbb

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies.

Authors:  Silke C Mueller; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2012-11-07       Impact factor: 2.953

Review 2.  Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

Review 3.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

5.  Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study.

Authors:  B Chaigne; P Gatault; F Darrouzain; C Barbet; D Degenne; M François; P Szymanski; N Rabot; G Golea; E Diot; F Maillot; Y Lebranchu; H Nivet; G Paintaud; J-M Halimi; L Guillevin; M Büchler
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

6.  Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.

Authors:  Hyeyoung Kim; Nam-Joon Yi; Juyeun Lee; Joohyun Kim; Mi-Ra Moon; Jaehong Jeong; Jeong-Moo Lee; Tae Suk You; Suk-Won Suh; Min-Su Park; YoungRok Choi; Geun Hong; Hae Won Lee; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Clin Mol Hepatol       Date:  2014-09-25

7.  Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients.

Authors:  Jun Zhang; Zhi Sun; Zhenfeng Zhu; Jing Yang; Jian Kang; Guiwen Feng; Lin Zhou; Lihua Zuo; Yonggang Luo; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

Review 8.  Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.

Authors:  David K Metz; Nick Holford; Joshua Y Kausman; Amanda Walker; Noel Cranswick; Christine E Staatz; Katherine A Barraclough; Francesco Ierino
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

9.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.